Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Summary
This study is a multicenter, open-label, dose-finding/efficacy-expanding Phase IB/II clinical trial to evaluate SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer. The study consists of two phases: Phase IB to explore the safety/tolerability of SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer; Phase II: To explore the efficacy of SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer.
Official title: Safety, Tolerability, and Efficacy of SHR-A2102 in Combination With Adebrelimab, With SHR-8068, in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase IB/II Open-Label, Multicenter Clinical Study
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
124
Start Date
2024-09-27
Completion Date
2026-04-30
Last Updated
2024-11-12
Healthy Volunteers
No
Conditions
Interventions
SHR-A2102
SHR-A2102: injection, 80mg/ bottle, intravenous drip
Adebelimab (SHR-1316)
Adebelimab (SHR-1316): injection, 600mg(12mL)/ bottle, intravenous drip
SHR-8068
SHR-8068: injection, 50mg（10mL）/ bottle, intravenous drip
Locations (1)
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China